Table 4.
Effects on lipid profile (X ± SD)
| Treatment | Baseline | 12 weeks | 24 weeks | Changes (%) | ||
|---|---|---|---|---|---|---|
| Total cholesterol (mmol/l) | ||||||
| Abexol | 4.6 ±0.8 | 4.5 ±0.7 | 4.6 ±0.7 | 0.0 | ||
| Atorvastatin | 4.8 ±0.7 | 3.5 ±0.9*a | 4.0 ±0.9*a | –16.7 | ||
| Combined therapy | 4.5 ±0.9 | 3.4 ±0.8*a | 3.9 ±0.9*a | –13.3 | ||
| Diet + exercise | 5.1 ±0.9 | 4.7 ±0.9 | 4.8 ±0.9 | –5.9 | ||
| LDL-C (mmol/l) | ||||||
| Abexol | 2.9 ±0.8 | 2.9 ±0.7 | 2.9 ±0.7 | 0.0 | ||
| Atorvastatin | 3.1 ±0.5 | 2.0 ±0.9*a | 2.4 ±1.0*a | –22.6 | ||
| Combined therapy | 2.8 ±0.8 | 2.0 ±0.7*a | 2.1 ±0.9*a | –25.0 | ||
| Diet + exercise | 3.0 ±0.8 | 3.1 ±1.0 | 3.1 ±1.0 | +3.3 | ||
| HDL-C (mmol/l) | ||||||
| Abexol | 1.0 ±0.4 | 0.9 ±0.3 | 0.9 ±0.3 | –10.0 | ||
| Atorvastatin | 1.0 ±0.3 | 1.0 ±0.3 | 1.0 ±0.3 | 0.0 | ||
| Combined therapy | 1.0 ±0.2 | 1.0 ±0.3 | 1.1 ±0.3 | +10.0 | ||
| Diet + exercise | 1.0 ±0.3 | 0.9 ±0.3 | 1.0 ±0.3 | 0.0 | ||
| Triglycerides (mmol/l) | ||||||
| Abexol | 1.7 ±0.8 | 1.7 ±0.9 | 1.7 ±0.7 | 0.0 | ||
| Atorvastatin | 1.8 ±0.9 | 1.2 ±0.4*b | 1.2 ±0.5*b | –33.3 | ||
| Combined therapy | 1.6 ±0.8 | 1.3 ±0.6 | 1.5 ±0.7 | –6.3 | ||
| Diet + exercise | 1.8 ±1.1 | 1.8 ±1.2 | 1.9 ±1.3 | +5.6 | ||
X – mean, SD – standard deviation, *p < 0.05 comparison between groups (ANOVA test)
a
p < 0.05 comparison atorvastatin group and combined therapy group vs. Abexol group and vs. diet + exercise group (Scheffé test)
b
p < 0.05 comparison atorvastatin group vs. diet + exercise group (Scheffé test)